DGAP-News: Novavax Completes $100 Million Public Offering of Common Stock
(firmenpresse) - Novavax, Inc.
27.09.2013 17:30
---------------------------------------------------------------------------
ROCKVILLE, Md., 2013-09-27 17:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) today announced the closing of its previously
announced underwritten public offering of 31,846,950 shares of its common
stock, including 4,153,950 shares of common stock that were issued upon the
exercise in full of the over-allotment option granted to the underwriters.
The shares were sold at the public offering price of $3.14 per share, resulting
in total gross proceeds of $100 million dollars. Novavax will receive net
proceeds, after deducting underwriting discounts and commissions and offering
expenses, of approximately $94.6 million from the offering.
Lazard Capital Markets LLC acted as the sole book-running manager for the
offering, with Piper Jaffray&Co. and Wedbush PacGrow Life Sciences acting as
co-lead managers and Burrill Securities LLC acting as co-manager.
The shares described above were issued pursuant to a final prospectus
supplement and accompanying prospectus. The company filed the final prospectus
supplement relating to the offering with the Securities and Exchange Commission
('SEC') on September 24, 2013, which is available along with the accompanying
prospectus filed with the SEC in connection with the company's shelf
registration statement on Form S-3, previously declared effective by the SEC,
on the SEC's website at www.sec.gov. Copies of the final prospectus supplement
and the accompanying prospectus may be obtained by sending a request to: Lazard
Capital Markets LLC, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, or
via telephone at 800-542-0970.
This press release does not and shall not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines and vaccine adjuvants to address a broad range of infectious
diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle technology, the company produces vaccine candidates to efficiently
and effectively respond to both known and newly emergent diseases.
Forward-Looking Statements
Statements contained in this release, including those relating to the closing
of the offering, and those statements using words such as 'expects' and
'intends' are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in the forward-looking statements. These risks and uncertainties include, but
are not limited to: our ability to successfully complete the offering on terms
and conditions satisfactory to us; the possible adverse impact on the market
price of our shares of common stock due to the dilutive effect of the
securities to be sold in the offering; capital market risks; our ability to
raise additional capital when needed; and other risk factors identified from
time to time in the reports we file with Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which are available at www.sec.gov. We
caution investors not to place considerable reliance on the forward-looking
statements contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and we undertake
no obligation to update or revise any of the statements. Our business is
subject to substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give careful
consideration to these risks and uncertainties.
CONTACT: Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX
27.09.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Novavax, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US6700021040
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2013 - 17:30 Uhr
Sprache: Deutsch
News-ID 300933
Anzahl Zeichen: 1552
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 255 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Novavax Completes $100 Million Public Offering of Common Stock"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
